ARTICLE | Clinical News
Onyx regulatory update
May 3, 1999 7:00 AM UTC
ONXX received European Patent No. 689,447B1 claiming the use of adenoviruses modified to lack viral proteins that bind to the tumor suppressor protein p53 to treat patients whose cancers lack p53 func...